Amended Current Report Filing (8-k/a)
December 16 2019 - 5:18PM
Edgar (US Regulatory)
0000019446
true
0000019446
2019-09-30
2019-10-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant To Section 13 Or 15(d) of
The Securities Exchange Act of 1934
Date
of earliest event reported: October 1, 2019
CANTEL MEDICAL CORP.
(Exact Name of Registrant as Specified in
its Charter)
Delaware
|
|
001-31337
|
|
22-1760285
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
150 Clove Road, Little Falls, New Jersey
|
|
07424
|
|
(973) 890-7220
|
(Address of Principal Executive Offices)
|
|
(Zip code)
|
|
(Registrant’s telephone number,
including area code)
|
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Common Stock
|
|
CMD
|
|
New York Stock Exchange
|
(Title of each class)
|
|
(Trading Symbol)
|
|
(Name of each exchange on which
registered)
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Explanatory Note
As previously reported on its Current Report on Form 8-K filed with the Securities and Exchange Commission
(the "SEC") on October 2, 2019 (the "Original Report"), Cantel Medical Corp. (the "Company"), completed
its previously announced acquisition of Hu-Friedy Mfg. Co., LLC ("Hu-Friedy") from Dental Holding, LLC ("Dental Holding"),
pursuant to that certain Purchase and Sale Agreement, dated as of July 29, 2019, by and among the Company, Hu-Friedy, Dental Holding,
and, for limited purposes set forth therein, Ken Serota and Ron Saslow (the "Hu-Friedy Acquisition"). For a description
of the Hu-Friedy Acquisition and the related agreements, see the Company’s Current Report on Form 8-K filed with the SEC
on July 30, 2019. This Current Report on Form 8-K/A is being filed by the Company solely for the purpose of amending and supplementing
the Original Report to provide the financial statements and pro forma financial information relating to the Hu-Friedy Acquisition
required by Items 9.01(a) and (b) of Form 8-K, respectively.
As previously reported on its Current Report on Form 8-K filed
with the Securities and Exchange Commission (the “SEC”) on October 2, 2019 (the “Original Report”),
Cantel Medical Corp. (the “Company”), completed its previously announced acquisition of Hu-Friedy Mfg. Co.,
LLC (“Hu-Friedy”) from Dental Holding, LLC (“Dental Holding”), pursuant to that certain
Purchase and Sale Agreement, dated as of July 29, 2019, by and among the Company, Hu-Friedy, Dental Holding, and, for limited
purposes set forth therein, Ken Serota and Ron Saslow (the “Hu-Friedy Acquisition”). For a description of the
Hu-Friedy Acquisition and the related agreements, see the Company’s Current Report on Form 8-K filed with the SEC on
July 30, 2019. This Current Report on Form 8-K/A is being filed by the Company solely for the purpose of amending and supplementing
the Original Report to provide the financial statements and pro forma financial information relating to the Hu-Friedy Acquisition
required by Items 9.01(a) and (b) of Form 8-K, respectively.
Item 9.01. Financial Statements and Exhibits
(a) Financial Statements of Business to be Acquired.
|
·
|
The audited financial statements of Dental Holding as of and for the years ended December 31, 2018 and December 31,
2017, the notes related thereto and the report of RSM US LLP, independent registered public accounting firm, dated March
8, 2019 are filed as Exhibit 99.1 hereto.
|
|
|
|
|
·
|
The audited financial statements of Dental Holding as of and for the years ended December 31, 2017 and December 31,
2016, the notes related thereto and the report of RSM US LLP, independent registered public accounting firm, dated
March 5, 2018 are filed as Exhibit 99.1 hereto.
|
|
·
|
The interim unaudited financial statements of Dental Holding as of June 30, 2019, and for the six
months ended June 30, 2019 and 2018 and the notes related thereto, are filed as
Exhibit 99.2 hereto.
|
(b) Pro forma financial information.
|
·
|
Unaudited pro forma condensed combined statement of income of the Company for the year ended July 31,
2019, and the notes related thereto, are
filed as Exhibit 99.3 hereto.
|
(d) Exhibits.
Exhibit No.
|
|
Description of Exhibit
|
|
|
|
23.1
|
|
Consent of RSM US LLP, Independent Registered Public Accounting Firm
|
|
|
|
99.1
|
|
Audited financial statements of Dental Holding
as of and for the years ended December 31, 2018 and December 31, 2017, the notes related thereto and the report of RSM US LLP,
independent registered public accounting firm, dated March 8, 2019.
|
|
|
|
|
|
Audited financial statements of Dental Holding as of and for the years ended December 31, 2017 and December 31,
2016, the notes related thereto and the report of RSM US LLP, independent registered public accounting firm, dated
March 5, 2018.
|
|
|
|
99.2
|
|
Unaudited financial statements of
Dental Holding as of June 30, 2019 and for the six months ended June 30, 2019 and 2018, and the notes related
thereto.
|
|
|
|
99.3
|
|
Unaudited
pro forma condensed combined statement of income of the Company for the year ended July 31, 2019, and the
notes related thereto.
|
|
|
|
104
|
|
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CANTEL MEDICAL CORP.
|
|
(Registrant)
|
|
|
|
|
|
|
Date: December 16, 2019
|
By:
|
/s/ Brian R. Capone
|
|
|
Brian R. Capone
|
|
|
Senior Vice President, Corporate Controller and Chief Accounting Officer
|
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jul 2023 to Jul 2024